Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
NCT07235059Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of OJR520 in chronic kidney disease (CKD) (17 arms), sponsored by Novartis. Primary endpoint: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs). Started Nov 2025; status: recruiting.
02
Drugs
OJR520
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07235059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235059.